Careers  |  Sign In  |  Register

NSCLC Content Hub

Navigating New Immune-Based Combinations in Advanced NSCLC

Joshua K. Sabari, MD, assistant professor, Department of Medicine, NYU Langone Health’s Perlmutter Cancer Center, discusses the limited treatment options for non-small cell lung cancer (NSCLC) patients without known driver mutations. Dr. Sabari recommends pembrolizumab for patients with high PDL-1, while a combination of pembrolizumab and platinum-doublet chemotherapy is recommended for patients with low PDL-1. He also emphasizes the need for additional predictive biomarkers to identify subsets of patients who may benefit from alternative immune therapies.

Read more by clicking here.